<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="publisher-id">abd</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26560229</article-id>
      <article-id pub-id-type="pmc">4631249</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20154387</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letters</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Do steroid hormones have an important role on cutaneous lupus
physiopathology?<xref ref-type="fn" rid="fn01">*</xref></article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Brasileiro</surname>
            <given-names>Ana</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Campos</surname>
            <given-names>Sara</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fidalgo</surname>
            <given-names>Ana</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <aff id="aff01"><label>1</label>Hospital S. Ant&#xF3;nio dos Capuchos - Centro Hospitalar
Lisboa Central &#x2013; Lisbon, Portugal.</aff>
      </contrib-group>
      <author-notes>
        <corresp id="c01">MAILING ADDRESS: Ana Brasileiro, Alameda Santo Ant&#xF3;nio dos Capuchos
1169-050, Lisbon, Portugal. E-mail: <email>afmbrasileiro@gmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>Sep-Oct</season>
        <year>2015</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>Sep-Oct</season>
        <year>2015</year>
      </pub-date>
      <volume>90</volume>
      <issue>5</issue>
      <fpage>766</fpage>
      <lpage>768</lpage>
      <history>
        <date date-type="received">
          <day>10</day>
          <month>1</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>19</day>
          <month>2</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2015 by Anais Brasileiros de Dermatologia</copyright-statement>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p>
        </license>
      </permissions>
    </article-meta>
  </front>
  <body>
    <p>Sir,</p>
    <p>An 80-year-old-Caucasian-woman has been followed during the last 25 years for cutaneous
discoid lupus erythematosus (CDLE) without systemic involvement. The lesions, limited to
the face, ears and scalp, had been controlled with photoprotection, topical
corticosteroids, topical calcineurin inhibitors and hydroxychloroquine, combined
intermittently with intralesional and systemic steroids. Her medical history was otherwise
not relevant and she had never been a smoker.</p>
    <p>Four years ago she underwent radical left mastectomy for carcinoma ductal <italic>in
situ</italic> with positive oestrogen receptors, followed by hormonotherapy with
letrozole 2,5mg/day. A month later there was pronounced cutaneous worsening and the lesions
became refractory to previously effective therapies (<xref ref-type="fig" rid="f01">Figure
1</xref>). There were no other recently started medications or systemic complaints;
routine blood laboratory tests and autoimmunity antibodies were within normal range.
Acitretin 25mg/day was attempted but there was further clinical worsening and
immunosuppressive therapies were contraindicated by the recent malignant neoplasia.
Thalidomide 50mg/day was then combined with previous therapies, with marked clinical
improvement within two weeks, allowing the discontinuation of systemic steroids and
hydroxychloroquine (<xref ref-type="fig" rid="f02">Figure 2</xref>). Sustained therapeutic
efficacy was observed over one-year follow-up despite maintenance of letrozole therapy. No
significant side effects have occurred.</p>
    <fig id="f01" orientation="portrait" position="float">
      <label>Figure 1</label>
      <caption>
        <p>A: Multiple well-defined erythematous plaques distributed over convex areas of the
face; B: Marked inflammatory infiltration of the scalp with follicular plugging,
adherent scale and alopecia</p>
      </caption>
      <graphic xlink:href="abd-90-05-0766-g01"/>
    </fig>
    <fig id="f02" orientation="portrait" position="float">
      <label>Figure 2</label>
      <caption>
        <p>Improvement of facial lesions with residual plaques</p>
      </caption>
      <graphic xlink:href="abd-90-05-0766-g02"/>
    </fig>
    <p>Lupus erythematosus (LE) has three major subtypes: systemic lupus erythematosus (SLE),
subacute lupus erythematosus (SCLE) and cutaneous discoid lupus erythematosus (CDLE). The
pathogenesis is not well known - it is believed to stem from interplay between genetic and
environmental factors. Ultraviolet radiation and immune dysregulation of innate and
acquired immune responses have been implicated.<sup><xref rid="r01" ref-type="bibr">1</xref></sup> Hormonal-influenced mechanisms might also play a role in LE. The skin
is an independent steroidogenic organ, and cutaneous steroidogenesis has effects on local
immunologic activity. Oestrogen stimulates the production of interferon-y, interleukin 1,
5, 6 and 10, increases B-cell survival, enhances antibody production and contributes to the
persistence of autoreactive T-cells in SLE patients.<sup><xref rid="r02" ref-type="bibr">2</xref></sup></p>
    <p>Additionally, epidemiological data supports a role for sexual hormones in lupus
susceptibility.<sup><xref rid="r01" ref-type="bibr">1</xref></sup> An estimated
three-fold female predominance among patients with cutaneous lesions only has been
observed.<sup><xref rid="r01" ref-type="bibr">1</xref></sup> The female preponderance
is even higher in SLE patients, occurring most commonly in reproductive-age women and being
rare in prepubertal age.<sup><xref rid="r01" ref-type="bibr">1</xref></sup> Furthermore,
reported cases of hormonal-induced SLE and anti-oestrogen drug-induced SCLE, namely
anastrozole and tamoxifen, also suggest a role for hormonal imbalance in LE
pathogenesis.<sup><xref rid="r03" ref-type="bibr">3</xref>-<xref rid="r05" ref-type="bibr">5</xref></sup> However, no case of CDLE induced or aggravated by such
therapies has been reported to date.</p>
    <p>Letrozole is a third-generation aromatase inhibitor indicated for hormone-sensitive breast
cancer in postmenopausal women. Its anti-oestrogenic effects induce nearly complete
suppression of aromatization in all tissues. Theoretically, aromatase inhibitors should be
beneficial in lupus patients, once they reduce cutaneous estradiol production which
stimulates inflammatory pathways. Conversely, in our patient, letrozole paradoxically
aggravated the disease, perhaps due to iatrogenic hormonal imbalance, which points towards
a pathogenic role for cutaneous hormonal dysregulation in CLE.</p>
    <p>Considering that both pathologies are not rare, probably more CLE women will undergo
anti-oestrogen therapy for breast cancer. Whether the cutaneous disease will have the same
behaviour as in our patient remains unknown. Further studies are warranted to access the
effect of aromatase inhibitors in CLE patients.</p>
  </body>
  <back>
    <fn-group>
      <fn fn-type="conflict">
        <p>Conflict of Interest: None.</p>
      </fn>
      <fn fn-type="supported-by">
        <p>Financial Support: None.</p>
      </fn>
      <fn fn-type="other">
        <p><bold>How to cite this article:</bold> Brasileiro A, Campos S, Fidalgo A. Do steroid
hormones have an important role on cutaneous lupus physiopathology? An Bras Dermatol.
2015; 90(5):766-8.</p>
      </fn>
      <fn fn-type="other" id="fn01">
        <label>*</label>
        <p>Work carried out at the Hospital S. Ant&#xF3;nio dos Capuchos - Centro Hospitalar Lisboa
Central &#x2013; Lisbon, Portugal.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="r01">
        <label>1</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Bolognia</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Jorizzo</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Rapini</surname>
              <given-names>RP</given-names>
            </name>
          </person-group>
          <source>Dermatology</source>
          <edition>3rd ed</edition>
          <publisher-loc>Mosby</publisher-loc>
          <publisher-name>Elsevier</publisher-name>
          <year>2012</year>
          <fpage>615</fpage>
          <lpage>629</lpage>
        </element-citation>
      </ref>
      <ref id="r02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>WU</given-names>
            </name>
            <name>
              <surname>Min</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Hwang</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Yoo</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Cho</surname>
              <given-names>CS</given-names>
            </name>
          </person-group>
          <article-title>Effect of oestrogen on T cell apoptosis in patients with systemic
lupus erythematosus</article-title>
          <source>Clin Exp Immunol</source>
          <year>2010</year>
          <volume>161</volume>
          <fpage>453</fpage>
          <lpage>458</lpage>
          <pub-id pub-id-type="pmid">20529085</pub-id>
        </element-citation>
      </ref>
      <ref id="r03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chan</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Mok</surname>
              <given-names>CC</given-names>
            </name>
          </person-group>
          <article-title>Development of systemic lupus erythematosus in a male-to-female
transsexual: the role of sex hormones revisited</article-title>
          <source>Lupus</source>
          <year>2013</year>
          <volume>22</volume>
          <fpage>1399</fpage>
          <lpage>1402</lpage>
          <pub-id pub-id-type="pmid">23897544</pub-id>
        </element-citation>
      </ref>
      <ref id="r04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Trancart</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cavailhes</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Balme</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Skowron</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Anastrozole-induced subacute cutaneous lupus
erythematosus</article-title>
          <source>Br J Dermatol</source>
          <year>2008</year>
          <volume>158</volume>
          <fpage>628</fpage>
          <lpage>629</lpage>
          <pub-id pub-id-type="pmid">18070201</pub-id>
        </element-citation>
      </ref>
      <ref id="r05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fumal</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Danchin</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cosserat</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Barbaud</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Schmutz</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
          <article-title>Subacute cutaneous lupus erythematosus associated with tamoxifen
therapy: two cases</article-title>
          <source>Dermatology</source>
          <year>2005</year>
          <volume>210</volume>
          <fpage>251</fpage>
          <lpage>252</lpage>
          <pub-id pub-id-type="pmid">15785062</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
